Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Depreciation & Amortization (CF) (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 7.06% year-over-year to $1.9 million, compared with a TTM value of $7.5 million through Dec 2025, down 12.72%, and an annual FY2025 reading of $7.5 million, down 12.72% over the prior year.
  • Depreciation & Amortization (CF) was $1.9 million for Q4 2025 at Amicus Therapeutics, up from $1.9 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.2 million in Q3 2023 and bottomed at $1.3 million in Q1 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $1.8 million, with a median of $1.8 million recorded in 2025.
  • The sharpest move saw Depreciation & Amortization (CF) crashed 40.4% in 2021, then soared 73.25% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $1.5 million in 2021, then dropped by 13.64% to $1.3 million in 2022, then soared by 66.44% to $2.2 million in 2023, then dropped by 6.46% to $2.0 million in 2024, then fell by 7.06% to $1.9 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for FOLD at $1.9 million in Q4 2025, $1.9 million in Q3 2025, and $1.9 million in Q2 2025.